| Date | Title | Description |
| 27.03.2026 | The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB | The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
Fri, Mar 27, 2026 08:00 CET Report this content
Stockholm March 27, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) her... |
| 23.03.2026 | New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress | New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
Mon, Mar 23, 2026 08:30 CET Report this content
Stockholm, Sweden, March 23, 2026 – BioArctic’s AB (publ) (Nasdaq Stockholm: BIOA B) partner Ei... |
| 22.03.2026 | Excalipoint Therapeutics Secures $68.7M for Next-Gen TCE Therapies | Excalipoint Therapeutics, a dynamic Shanghai-based biotechnology firm, secured $68.7 million in oversubscribed seed funding. This substantial capital propels its mission to redefine T-cell engager (TCE) therapies. The company is tackling si... |
| 18.03.2026 | Excalipoint Therapeutics: $68.7 Million Raised For Next-Generation T-Cell Engager Therapies | Excalipoint Therapeutics, a clinical-stage biotechnology company focused on next-generation T-cell engager therapies, announced the close of an oversubscribed $68.7 million seed financing round to advance its proprietary platforms and pipel... |
| 18.03.2026 | Demeetra Announces Renewal of piggyBac® Technology Research License by Eisai
USA - English USA - English | Demeetra AgBio, Inc. (hereafter "Demeetra") today announced that the renewal of the research license agreement for the piggyBac® transposase technology, a widely used platform for genetic engineering in research applications, by E... |
| 18.03.2026 | Excalipoint Therapeutics Raises $68.7M in Seed Funding | Excalipoint Therapeutics, a Shanghai, China-based biotechnology company developing T-cell engager (TCE) therapies for cancer and autoimmune diseases, raised $68.7M in Seed funding.
Backers included HSG, Apricot Capital, Yuanbio Venture Capi... |
| 11.03.2026 | Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress | Latest data on long-term, real-world treatment with lecanemab will be presented at the AD/PD™ 2026 congress
Wed, Mar 11, 2026 08:00 CET Report this content
Stockholm, Sweden, March 11, 2026 – BioArctic’s AB (publ) (Nasdaq Stockholm: BIOA B)... |
| 27.02.2026 | Number of shares and votes in BioArctic AB (publ) as of February 27, 2026 | Number of shares and votes in BioArctic AB (publ) as of February 27, 2026
Fri, Feb 27, 2026 18:30 CET Report this content
Stockholm, February 27, 2026 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued ... |
| 21.02.2026 | Sift Biosciences Raises $3.7 Million Pre-Seed To Advance T-Cell Booster Platform | Sift Biosciences has closed an oversubscribed $3.7 million pre-seed financing round to accelerate development of its next-generation peptide immunotherapy platform designed to activate pre-existing memory T cells. The round was co-led by Fr... |
| 19.02.2026 | Sift Biosciences Raises $3.7M in Pre-Seed Funding | Sift Biosciences, a San Carlos, CA-based provider of a peptide-based immunotherapy platform, raised $3.7M in Pre-Seed funding.
The round was co-led by Lifespan Vision Ventures and Freeflow Ventures, with participation from Valuence Ventures... |
| 19.02.2026 | Lifespan Vision Ventures Co-Leads Sift Biosciences' $3.7M Pre-Seed Financing | NORWALK, Conn., Feb. 19, 2026 /PRNewswire/ -- Lifespan Vision Ventures, an investment firm focused on therapeutics that improve human healthspan, today announced that it has co-led Sift Biosciences' oversubscribed $3.7 million Pre-Seed fina... |
| 18.02.2026 | Interim Report for the period October – December 2025 | Interim Report for the period October – December 2025
Wed, Feb 18, 2026 08:00 CET Report this content
A transformative year with record financial results
Events during the fourth quarter 2025 Leqembi® Iqlik™ was launched for weekly maintena... |
| 17.02.2026 | To the shareholders of H. Lundbeck A/S | To the shareholders of H. Lundbeck A/S
Tue, Feb 17, 2026 10:00 CET Report this content NOTICE OF ANNUAL GENERAL MEETING
Notice is hereby given of the annual general meeting of H. Lundbeck A/S to be held on: WEDNESDAY, 18 MARCH 2026 AT 10:00... |
| 11.02.2026 | Invitation to presentation of BioArctic’s fourth quarter report for October – December 2025 on February 18 at 9.30 a.m. CET | Invitation to presentation of BioArctic’s fourth quarter report for October – December 2025 on February 18 at 9.30 a.m. CET
Wed, Feb 11, 2026 08:30 CET Report this content
Stockholm, Sweden, February 11, 2026 – BioArctic AB (publ) (Nasdaq S... |
| 09.02.2026 | BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China | BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China
Mon, Feb 09, 2026 06:45 CET Report this content
Stockholm, Sweden, February 9, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announ... |
| 06.02.2026 | Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025 | Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
Fri, Feb 06, 2026 12:00 CET Report this content
Stockholm, Sweden, February 6, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the p... |
| 05.02.2026 | Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan | TOKYO and SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, "Henlius") announced to... |
| 03.02.2026 | Total Investment of Approx. USD 8.8 Million in Malaria, Tuberculosis, and NTD R&D Projects with Partners Including Mahidol University, Barcelona Institute for Global Health, and Eisai | TOKYO, Feb. 3, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.39 billion (USD 8.8 million1) in six R&D projects for the development of drugs, diagnostic... |
| 26.01.2026 | Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA | Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA
Mon, Jan 26, 2026 00:30 CET Report this content
Stockholm, Sweden, January 26, 2026 – Bio... |
| 26.01.2026 | Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab) | Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
Mon, Jan 26, 2026 22:00 CET Report this content
Stockholm, Sweden, January 26, 2026 – BioArctic AB's (publ)... |
| 06.01.2026 | BLA for subcutaneous formulation of Leqembi® accepted in China | BLA for subcutaneous formulation of Leqembi® accepted in China
Tue, Jan 06, 2026 12:00 CET Report this content
Stockholm, Sweden, Januari 6, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biol... |
| 30.12.2025 | Novo Nordisk’s ‘long game’ on weight loss drugs sparks hope in science, but the Street is impatient | Novo Nordisk has had a difficult year as investors questioned the company’s ability to translate its strides in pioneering GLP-1 drugs to financial gains.
Scientists, however, say that Novo’s medicine still has potential.
What started with ... |
| 18.12.2025 | PRISM BioLab and Talus Bioscience Join Forces to Discover Novel Inhibitors of Transcription Factor and Protein-Protein Interaction Targets | TOKYO, Dec. 18, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM") and Talus Bioscience, Inc. ("Talus Bio") announced today that they entered into a collaboration to discover novel Inhibitors of transcription factor (... |
| 25.11.2025 | Eisai completes U.S. rolling sBLA submission for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose | Eisai completes U.S. rolling sBLA submission for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose
Tue, Nov 25, 2025 13:37 CET Report this content
Stockholm, Sweden, November 25, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm... |
| 24.11.2025 | Novo Nordisk shares plunge after Alzheimer’s drug trial fails to hit key target | Analysts had prior to the results called the trial a long shot, whereas Novo itself had referred to it as a “lottery ticket.”
The trial tested whether semaglutide — the active ingredient in Novo’s blockbuster diabetes and weight loss drugs ... |
| 14.11.2025 | PRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd. | TOKYO, Nov. 14, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM") announces that today, PRISM and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka; President and COO: Toichi Takino; hereinafter "Ono") have achieved ... |
| 04.11.2025 | Invitation to presentation of BioArctic’s third quarter report for July – September 2025 on November 13 at 9.30 a.m. CET | Invitation to presentation of BioArctic’s third quarter report for July – September 2025 on November 13 at 9.30 a.m. CET
Tue, Nov 04, 2025 10:00 CET Report this content
Stockholm, Sweden, November 3, 2025 – BioArctic AB (publ) (Nasdaq Stock... |
| 30.10.2025 | Sales of Leqembi® totaled 18 billion yen in the third quarter 2025 | Sales of Leqembi® totaled 18 billion yen in the third quarter 2025
Thu, Oct 30, 2025 11:00 CET Report this content
Stockholm, Sweden, October 30, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the prel... |
| 27.10.2025 | Health Canada Grants Authorization for Leqembi® (lecanemab) | Health Canada Grants Authorization for Leqembi® (lecanemab)
Mon, Oct 27, 2025 00:35 CET Report this content
Stockholm, October 27, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has ... |
| 17.10.2025 | BioArctic presents Nomination Committee | BioArctic presents Nomination Committee
Fri, Oct 17, 2025 15:00 CET Report this content
Stockholm, Sweden, October 17, 2025 – Pursuant to the instruction regarding the appointment of the Nomination Committee, BioArctic AB (publ) (Nasdaq Sto... |
| 14.10.2025 | Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025 | Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
Tue, Oct 14, 2025 07:00 CET Report this content
Stockholm, October 14, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced ... |
| 14.10.2025 | First patient treated with Leqembi® (lecanemab) in the Nordics | First patient treated with Leqembi® (lecanemab) in the Nordics
Tue, Oct 14, 2025 09:05 CET Report this content
Stockholm, October 14, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Leqembi has now been made avail... |
| 06.10.2025 | Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S. | Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
Mon, Oct 06, 2025 22:35 CET Report this content
Stockholm, October 6, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lec... |
| 30.09.2025 | James Mackay is tending to 'unfinished business' with new gout biotech and $205M fundraise | In this market, three things make fundraising easier for a biotech: a derisked asset touting a well-defined profile and an experienced team to guide the program’s development.
Crystalys Therapeutics has checked all three boxes, proving that... |
| 24.09.2025 | Leqembi® approved for the treatment of early Alzheimer’s disease in Australia | Leqembi® approved for the treatment of early Alzheimer’s disease in Australia
Wed, Sep 24, 2025 08:40 CET Report this content
Stockholm, September 24, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) announced today that the Therapeu... |
| 09.09.2025 | Gunilla Osswald awarded Uppsala University Alumnus of the year 2025 | Gunilla Osswald awarded Uppsala University Alumnus of the year 2025
Tue, Sep 09, 2025 09:05 CET Report this content
Stockholm, Sweden, September 9, 2025 – Uppsala University announced today that BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA... |
| 04.09.2025 | AI Governance as Competitive Capability: The Pioneering Work of Sumesh Nair in Biopharma | Created by Carl Williams
Published: Sep 04 2025, 00:41 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 03.09.2025 | BioArctic’s founders intend to divest minor part of their shareholding | BioArctic’s founders intend to divest minor part of their shareholding
Wed, Sep 03, 2025 17:35 CET Report this content
Stockholm, September 3, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has been made aware that the company’s two ... |
| 03.09.2025 | Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer’s disease under Fast Track status | Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer’s disease under Fast Track status
Wed, Sep 03, 2025 01:30 CET Report this content
Stockholm, Se... |
| 01.09.2025 | Number of shares and votes in BioArctic AB (publ) as of August 29, 2025 | Number of shares and votes in BioArctic AB (publ) as of August 29, 2025
Mon, Sep 01, 2025 18:30 CET Report this content
Stockholm, September 1, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 10... |
| 29.08.2025 | US FDA approves Leqembi® IQLIK ™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer’s disease | US FDA approves Leqembi® IQLIK ™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer’s disease
Fri, Aug 29, 2025 23:55 CET Report this content
Stockholm, August 29, 2025 – BioArctic AB’s (publ... |
| 28.08.2025 | Interim Report for the period April – June 2025 | Interim Report for the period April – June 2025
Thu, Aug 28, 2025 08:00 CET Report this content
Increasing Leqembi® royalties and new partnership with Novartis
Events during the second quarter 2025 The European Commission granted Marketing ... |
| 26.08.2025 | BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties | BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties
Tue, Aug 26, 2025 07:05 CET Report this content
S... |
| 25.08.2025 | Leqembi® (lecanemab) launched in the EU today | Leqembi® (lecanemab) launched in the EU today
Mon, Aug 25, 2025 09:00 CET Report this content
Stockholm, August 25, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the launch of Leqembi in the EU s... |
| 21.08.2025 | Invitation to presentation of BioArctic’s second quarter report for April – June 2025 on August 28 at 9.30 a.m. CET | Invitation to presentation of BioArctic’s second quarter report for April – June 2025 on August 28 at 9.30 a.m. CET
Thu, Aug 21, 2025 09:00 CET Report this content
Stockholm, Sweden, August 21, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: ... |
| 21.08.2025 | Availity Invests $4.3 Million to Set Up New GCC in Bengaluru, Steps Up Hiring The company's India GCC workforce doubled in 2025, with year-end headcount projected at 3.5 times of what it was in Januar... | Availity, US-based real-time health information network, has invested USD 4.3 million to expand its India operations by opening a 54,000 sq. ft. facility in Bengaluru, India. The facility marks a significant step in the evolution of Availit... |
| 13.08.2025 | India Witnesses a Fresh Wave of Marquee GCC Setups and Large-Scale Expansions in July Companies are doubling down on India's strategic value— driven by access to deep digital talent, operational resil... | India has witnessed a fresh wave of marquee global capability centre (GCC) setups and large-scale expansions in July strengthening its position as the global hub for GCCs.
"From Fortune 500 giants to emerging tech innovators, companies... |
| 06.08.2025 | Quantifying the ROI of Compliance: Sumesh Nair on Architecting Risk-Based AI Validation for Modern Clinical Trials | Share
Share
Share
Share
Email
For any new therapy to reach the patients who need it, it must first navigate a formidable and complex global regulatory landscape. In the life sciences industry, this landscape is built upon a foundational set... |
| 04.08.2025 | After Hengrui’s USD 500 million deal with GSK, which biotech firms are next in line? | Last month, Hengrui Pharmaceuticals announced a blockbuster licensing deal with GSK worth up to USD 12.5 billion, with an upfront payment of USD 500 million. The deal grants GSK the overseas rights to Hengrui’s HRS-9821 as well as exclusive... |
| 31.07.2025 | Neurophet Showcases Full-Cycle Brain Imaging Analysis Solutions for Alzheimer's disease Including 'Neurophet AQUA AD' at AAIC 2025 | Showcased brain imaging analysis products such as Neurophet AQUA AD, capable of monitoring side effects of Alzheimer's disease treatments
Engaged in partnering with global big pharma and neurology KOLs, seeking global development collaborat... |
| 31.07.2025 | Latest data presented at AAIC 2025 reinforces lecanemab’s clinical effect with consistent safety profile | Latest data presented at AAIC 2025 reinforces lecanemab’s clinical effect with consistent safety profile
Thu, Jul 31, 2025 01:30 CET Report this content
Stockholm, Sweden, July 31, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) par... |
| 31.07.2025 | RESEARCH ADVANCES FROM THE 2025 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE | TORONTO, July 31, 2025 /PRNewswire/ -- New research results reported at the Alzheimer's Association International Conference® 2025 (AAIC®) advanced scientific understanding of risk, diagnosis and treatment of Alzheimer's disease and other d... |
| 31.07.2025 | Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025 | Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
Thu, Jul 31, 2025 12:00 CET Report this content
Stockholm, Sweden, July 31, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the prel... |
| 22.07.2025 | Lecanemab four-year efficacy and safety data to be presented at AAIC 2025 | Lecanemab four-year efficacy and safety data to be presented at AAIC 2025
Tue, Jul 22, 2025 08:00 CET Report this content
Stockholm, Sweden, July 22, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the lat... |
| 16.07.2025 | The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association | The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association
Wed, Jul 16, 2025 09:30 CET Report this content
Stockholm, Sweden, July 16, 2025– BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA... |
| 26.06.2025 | Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize | Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize
Thu, Jun 26, 2025 10:15 CET Report this content
Stockholm, Sweden, June 26, 2025– BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic's fou... |
| 13.06.2025 | BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review | BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review
Fri, Jun 13, 2025 08:00 CET Report this content
Stockholm, June 13, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the... |
| 04.06.2025 | BioArctic: A Beacon of Hope in Neurodegenerative Treatment | In the heart of Stockholm, BioArctic AB is charting a bold course through the murky waters of neurodegenerative diseases. The company recently held its Capital Markets Day, a gathering that felt more like a rallying cry than a corporate eve... |
| 02.06.2025 | BioArctic’s Capital Markets Day 2025 – entering a new era of growth | BioArctic’s Capital Markets Day 2025 – entering a new era of growth
Mon, Jun 02, 2025 10:30 CET Report this content
Stockholm, June 2, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today welcomes investors, analysts and financial me... |
| 30.05.2025 | Number of shares and votes in BioArctic AB (publ) as of May 30, 2025 | Number of shares and votes in BioArctic AB (publ) as of May 30, 2025
Fri, May 30, 2025 18:30 CET Report this content
Stockholm, May 30, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 3,000 Clas... |
| 28.05.2025 | China Approves New Insomnia Therapy From Japanese Drugmaker Eisai | (Yicai) May 28 -- China has approved the use of Dayvigo, a new insomnia therapy developed by Japanese pharmaceutical company Eisai.
Dayvigo can be used in China for the treatment of adults with insomnia, characterized by difficulties with s... |
| 23.05.2025 | Innovations in Oncology: A Look Ahead to ASCO 2025 | The American Society of Clinical Oncology (ASCO) Annual Meeting is a beacon for cancer research. This year, it shines brightly in Chicago from May 30 to June 3, 2025. The event promises a treasure trove of insights into groundbreaking thera... |
| 23.05.2025 | Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting | Abstract Released for E7386, Co-Developed Through Collaborative Research Between Eisai and PRISM
TOKYO, May 23, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company desig... |
| 22.05.2025 | BioArctic and Tubulis: Pioneering New Frontiers in Biopharma | In the ever-evolving landscape of biopharmaceuticals, two companies stand out: BioArctic and Tubulis. Both are making waves with innovative treatments that promise to change the game for patients suffering from neurodegenerative diseases an... |
| 22.05.2025 | Bulletin from the Annual General Meeting in BioArctic AB (publ) | Bulletin from the Annual General Meeting in BioArctic AB (publ)
Thu, May 22, 2025 18:18 CET Report this content
Stockholm, 22 May 2025. Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm today... |
| 22.05.2025 | BioArctic receives positive opinion for Orphan Medicinal Product Designation in the EU for exidavnemab in Multiple System Atrophy | BioArctic receives positive opinion for Orphan Medicinal Product Designation in the EU for exidavnemab in Multiple System Atrophy
Thu, May 22, 2025 15:15 CET Report this content
Stockholm, May 22, 2025 – BioArctic AB (publ) (Nasdaq Stockhol... |
| 22.05.2025 | Navigating Neurological Disease Biomarkers -- Progress, Learnings and Future Directions, Upcoming Webinar Hosted by Xtalks | www.olink.com
In this free webinar, learn about the impact of emerging biomarkers, including endothelial, metabolic, immune, and inflammatory markers on the diagnosis and treatment of neurological diseases. The featured speakers will discus... |
| 21.05.2025 | Interim Report for the period January – March 2025 | Interim Report for the period January – March 2025
Wed, May 21, 2025 08:00 CET Report this content
Leqembi approved in the EU and billion-dollar license agreement with Bristol Myers Squibb came into effect
Events during the first quarter 20... |
| 15.05.2025 | Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 – March 2026) | Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 – March 2026)
Thu, May 15, 2025 06:00 CET Report this content
Stockholm, Sweden, May 15, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) part... |
| 13.05.2025 | Invitation to presentation of BioArctic’s first quarter report for January - March 2025 on May 21 at 9.30 a.m. CET | Invitation to presentation of BioArctic’s first quarter report for January - March 2025 on May 21 at 9.30 a.m. CET
Tue, May 13, 2025 08:30 CET Report this content
Stockholm, Sweden, May 13, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA... |
| 01.05.2025 | Sales of Leqembi[®] totaled 14.7 billion yen in the first quarter 2025 | Sales of Leqembi[®] totaled 14.7 billion yen in the first quarter 2025
Thu, May 01, 2025 12:45 CET Report this content
Stockholm, Sweden, May 1, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preli... |
| 30.04.2025 | MHRA to evaluate monthly intravenous maintenance dosing of Leqembi[®] for the treatment of early Alzheimer’s disease in the UK | MHRA to evaluate monthly intravenous maintenance dosing of Leqembi[®] for the treatment of early Alzheimer’s disease in the UK
Wed, Apr 30, 2025 09:30 CET Report this content
Stockholm, April 30, 2025 – BioArctic AB’s (publ) (Nasdaq Stockho... |
| 23.04.2025 | BioArctic's Annual General Meeting: A Crucial Gathering for Shareholders | On May 22, 2025, BioArctic AB will host its Annual General Meeting (AGM) in Stockholm. This event is a vital touchpoint for shareholders, where the company’s future direction will be discussed and decided. As the clock ticks down to this im... |
| 23.04.2025 | BioArctic receives European substance patent for exidavnemab | BioArctic receives European substance patent for exidavnemab
Wed, Apr 23, 2025 13:00 CET Report this content
Stockholm, April 22, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office, EPO, ha... |
| 22.04.2025 | BioArctic publishes the Annual Report and Sustainability Report for 2024 | BioArctic publishes the Annual Report and Sustainability Report for 2024
Tue, Apr 22, 2025 20:00 CET Report this content
Stockholm, April 22, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that the Annual Report for 2024 ha... |
| 16.04.2025 | EU approves Leqembi® (lecanemab) for treatment of early Alzheimer’s disease (Extended information) | EU approves Leqembi® (lecanemab) for treatment of early Alzheimer’s disease (Extended information)
Wed, Apr 16, 2025 01:10 CET Report this content
Stockholm, April 16, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai ha... |
| 15.04.2025 | The Future of Drug Development: A New Era of Innovation and Collaboration | In the world of pharmaceuticals, innovation is the lifeblood. The landscape is shifting, driven by collaboration and cutting-edge technology. Two recent developments illustrate this trend: the European Commission's impending decision on lec... |
| 14.04.2025 | PRISM BioLab and Elix Join Forces to Accelerate AI-Driven Drug Discovery for Protein-Protein Interaction Targets | Strategic Partnership Aims to Create Novel Drug Discovery Pipeline for Unmet Medical Needs by Combining PPI Control Technology with AI Drug Discovery Platform
TOKYO, April 14, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM BioLab&... |
| 14.04.2025 | The European Commission to make final decision on EU Marketing Authorisation for lecanemab | The European Commission to make final decision on EU Marketing Authorisation for lecanemab
Mon, Apr 14, 2025 13:00 CET Report this content
Stockholm, Sweden, April 14, 2025 – The European Commission (EC) has today disclosed information that... |
| 07.04.2025 | Exidavnemab and lecanemab data presented at the 2025 AD/PD™ congress | Exidavnemab and lecanemab data presented at the 2025 AD/PD™ congress
Mon, Apr 07, 2025 12:00 CET Report this content
Stockholm, April 7, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) presented data on exidavnemab and lecanemab at th... |
| 06.04.2025 | Pillar VC's New Fund: A Catalyst for Scientific Innovation | Pillar VC has struck gold with its latest venture, closing a $175 million Fund IV. This move elevates the firm’s total assets under management to over $500 million. It’s a bold step into the future, one that promises to bridge the gap betwe... |
| 04.04.2025 | The Tug of War in Alzheimer’s Treatment: Kisunla’s Setback and the Rise of Innovative RNA Technologies | In the ever-evolving landscape of medical science, the battle against Alzheimer’s disease is a high-stakes game. Eli Lilly & Co. recently faced a significant setback with its Alzheimer’s drug, Kisunla. The European Medicines Agency (EMA... |
| 01.04.2025 | The European Commission refers lecanemab decision to Appeal Committee | The European Commission refers lecanemab decision to Appeal Committee
Tue, Apr 01, 2025 12:00 CET Report this content
Stockholm, Sweden, April 1, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the... |
| 29.03.2025 | Eli Lilly Alzheimer’s Drug Kisunla Fails to Get EU Backing | (Bloomberg) -- Eli Lilly & Co.’s Alzheimer’s disease drug Kisunla failed to get the backing of European regulators, who said its benefits don’t outweigh the risk of potentially fatal bleeding in the brain.
Lilly had sought to get the dr... |
| 27.03.2025 | Latest data on lecanemab and exidavnemab to be presented at the 2025 AD/PD™ congress | Latest data on lecanemab and exidavnemab to be presented at the 2025 AD/PD™ congress
Thu, Mar 27, 2025 08:00 CET Report this content
Stockholm, March 27, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company... |
| 27.03.2025 | Invitation to BioArctic’s Capital Markets Day 2025 in Stockholm | Invitation to BioArctic’s Capital Markets Day 2025 in Stockholm
Thu, Mar 27, 2025 10:00 CET Report this content
Stockholm, March 27, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) is pleased to welcome investors, analysts and financi... |
| 25.03.2025 | BioArctic’s partner Eisai presents sales simulation for Leqembi® at its annual press conference | BioArctic’s partner Eisai presents sales simulation for Leqembi® at its annual press conference
Tue, Mar 25, 2025 07:50 CET Report this content
Stockholm, Sweden, March 25, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eis... |
| 18.03.2025 | BioArctic: Pioneering Hope in Neurodegenerative Disease Treatment | In the realm of medical innovation, few companies shine as brightly as BioArctic AB. This Swedish biopharma company is at the forefront of developing treatments for neurodegenerative diseases, a field often overshadowed by the complexity of... |
| 17.03.2025 | BioArctic receives Orphan Drug Designation for exidavnemab the US | BioArctic receives Orphan Drug Designation for exidavnemab the US
Mon, Mar 17, 2025 18:25 CET Report this content
Stockholm, March 17, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Pr... |
| 12.03.2025 | Lars Lannfelt, Pär Gellerfors, and Gunilla Osswald awarded Uppsala University’s Innovation and Entrepreneurship Prize | Lars Lannfelt, Pär Gellerfors, and Gunilla Osswald awarded Uppsala University’s Innovation and Entrepreneurship Prize
Wed, Mar 12, 2025 08:00 CET Report this content
Stockholm, Sweden, March 12, 2025 – Uppsala University announced today tha... |
| 06.03.2025 | The Lecanemab Dilemma: A Setback in Alzheimer’s Treatment in Australia | In a world where time is a precious commodity, the recent decision by Australia’s Therapeutic Goods Administration (TGA) to decline the registration of lecanemab for early Alzheimer’s disease (AD) feels like a cruel twist of fate. The drug,... |
| 06.03.2025 | Funding Cuts: A Looming Crisis in Global Health | In the realm of global health, funding is the lifeblood. Without it, progress stagnates, and lives hang in the balance. Recently, the World Health Organization (WHO) sounded the alarm. The United States, a key player in global health fundin... |
| 06.03.2025 | The Sound of Silence: WHO and ITU's New Standard for Gamers' Hearing Health | In a world where gaming has become a cultural phenomenon, the sound of victory often drowns out the whispers of caution. The World Health Organization (WHO) and the International Telecommunication Union (ITU) have stepped into this arena, l... |
| 03.03.2025 | Therapeutic Goods Administration decides not to register lecanemab in Australia | Therapeutic Goods Administration decides not to register lecanemab in Australia
Mon, Mar 03, 2025 09:00 CET Report this content
Stockholm, Sweden, March 3, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced toda... |
| 28.02.2025 | Number of shares and votes in BioArctic AB (publ) as of February 28, 2025 | Number of shares and votes in BioArctic AB (publ) as of February 28, 2025
Fri, Feb 28, 2025 18:30 CET Report this content
Stockholm, February 28,2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during F... |
| 28.02.2025 | The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer’s disease in the EU | The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer’s disease in the EU
Fri, Feb 28, 2025 14:00 CET Report this content
Stockholm, February 28, 2025 – BioArctic AB’s (publ) (... |
| 20.02.2025 | BioArctic's Bold Moves in Alzheimer's Treatment: A New Era of Hope | In the world of biopharmaceuticals, the race against neurodegenerative diseases is relentless. BioArctic AB, a Swedish company, is at the forefront of this battle, armed with innovative technologies and strategic partnerships. Recent develo... |
| 20.02.2025 | BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing | BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
Thu, Feb 20, 2025 06:30 CET Report this content
Stockholm, Sweden, February 20, 2... |
| 18.02.2025 | Leqembi® sales reaches €200 million – first sales milestone achieved | Leqembi® sales reaches €200 million – first sales milestone achieved
Tue, Feb 18, 2025 08:00 CET Report this content
Stockholm, Sweden, February 18, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArcti... |
| 17.02.2025 | The Future of Pharmaceuticals: Innovations and Challenges in 2025 | The pharmaceutical landscape is shifting. New technologies and innovative treatments are emerging, promising to change the way we approach healthcare. In 2025, two companies stand at the forefront: BioArctic and TAHO Pharmaceuticals. Each i... |
